Clinical Results From a Randomized,Double-Blind,Dose-Ranging Study of Pantoprazole in Children Aged 1 Through 5 Years With Symptomatic Histologic or Erosive Esophagitis

Abstract

In an 8-week, multicenter, randomized, double-blind study, we evaluated the efficacy and tolerability of pantoprazole (0.3mg/kg [low dose (LD)], 0.6 mg/kg [medium dose (MD)], and 1.2 mg/kg [high dose (HD)]) for delayed-release oral suspension (granules) in patients 1 to 5 years with documented symptoms of gastroesophageal reflux disease (GERD) and endoscopic evidence of reflux-related erosive esophagitis (EE) or histologic esophagitis (HE) consistent with GERD. Patients with HE were randomly assigned to LD, MD, or HD, and patients with EE, to MD or HD. A daily eDiary captured 5 individual GERD symptoms. A total of 60 patients (56 HE, 4 EE) were randomized. Mean weekly GERD symptom score (WGSS, sum of weekly mean frequency scores for 5 individual GERD symptoms) for the modified intention-to-treat HE population at the final week was improved with LD ( P < .001), MD (P = .063), and HD (P < 0.001) (paired t-tests). Patients with EE were healed at week 8. Adverse event incidences did not increase with dose.

Keywords

pediatrics treatment outcome proton pump inhibitors gastroesophageal reflux pantoprazole preschool child infant

Get full access to this article

View all access options for this article.

References

Gallo-Torres H. Briefing document for June 11, 2002 Advisory Committee meeting on the proton-pump inhibitor (PPI) template. Justification for studies in pediatric patients . http://www.fda.gov/ohrms/dockets/ac/02/briefing/3870B1_02_Briefing%20document.pdf. 2002. Accessed January 25, 2010.

Barron JJ , Tan H. , Spalding J. , Bakst AW , Singer J. Proton pump inhibitor utilization patterns in infants. J Pediatr Gastroenterol Nutr. 2007;45:421-427.

Orenstein SR , Hassall E. Infants and proton pump inhibitors: tribulations, no trials. J Pediatr Gastroenterol Nutr. 2007 ;45:395-398.

Colletti R. , Di Lorenzo C. Overview of pediatric gastroesophageal reflux disease and proton pump inhibitor therapy. J Pediatr Gastroenterol Nutr. 2003 ;37(Suppl 1):S7-S11.

Di Lorenzo C. , Winter HS Introduction. J Pediatr Gastroenterol Nutr. 2003;37(Suppl 1):S1.

PROTONIX® (pantoprazole sodium) delayed-release tablets and PROTONIX® (pantoprazole sodium) for delayed-release oral suspension (U.S. package insert). Collegeville, PA: Wyeth; 2009.

Tolia V. , Bishop P. , Tsou V. , Gremse D. , Soffer EF , Comer GM ; Members of the 322 Study Group. Multicenter, randomized, double-blind study comparing 10, 20 and 40 mg pantoprazole in children (5-11 years) with symptomatic gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr . 2006;42:384-391.

Tsou VM , Baker R. , Book L. , et al; 326 Study Group. Multicenter, randomized, double-blind study comparing 20 and 40 mg of pantoprazole for symptom relief in adolescents (12 to 16 years of age) with gastroesophageal reflux disease (GERD). Clin Pediatr ( Phila). 2006;45: 741-749.

Tammara B. , Orczyk G. , Nightingale C. , Hoy M. , Meng X. Bioavailability of the new pantoprazole spheroid formulation to the currently marketed tablet formulation in healthy adult subjects. AAPS J. 2004;6(Suppl 1). http://www.aapsj.org/abstracts/AM_2004/AAPS2004-000275.PDF. Accessed February 1, 2010.

10.

Hogan D. , Pratha V. , Riff D. , et al. Oral pantoprazole in the form of granules or tablets are pharmacodynamically equivalent in suppressing acid output in patients with gastro-oesophageal reflux disease and a history of erosive oesophagitis. Aliment Pharmacol Ther. 2007;26: 249-256.

11.

Tammara B. , Weisel K. , Katz A. , Meng X. Bioequivalence study of pantoprazole granules administered to healthy subjects: oral administration with applesauce and apple juice and by nasogastric tube . Am J Health Syst Pharm. 2009;66:1923-1928.

12.

Rudolph CD , Mazur LJ , Liptak GS , et al. Guidelines for evaluation and treatment of gastroesophageal reflux in infants and children: recommendations of the North American Society for Pediatric Gastroenterology and Nutrition. J Pediatr Gastroenterol Nutr. 2001;32(Suppl 2):S1-S31.

13.

Vakil N. , van Zanten SV , Kahrilas P. , Dent J. , Jones R. ; Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol . 2006;101:1900-1920.

14.

Sherman PM , Hassall E. , Fagundes-Neto U. , et al. A global, evidence-based consensus on the definition of gastroesophageal reflux disease in the pediatric population. Am J Gastroenterol . 2009;104:1278-1295.

15.

Vandenplas Y. , Rudolph CD , Di Lorenzo C. , et al. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society of Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society of Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr. 2009;49:498-547.

16.

Deal L. , Gold B. , Gremse D. , et al. Age-specific questionnaires distinguish GERD symptom frequency and severity in infants and young children: development and initial validation . J Pediatr Gastroenterol Nutr. 2005;41: 178-185.

17.

Hetzel D. , Dent J. , Reed W. , et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology. 1988;95:903-912.

18.

Comer G. , Tammara B. , Adcock K. , et al. Pharmacokinetics of intravenous pantoprazole in children ages 1 to 16 years. Am J Gastroenterol. 2005;100(Suppl 9s):s373.

19.

Orenstein S. , Shalaby T. , Cohn J. Reflux symptoms in 100 normal infants: diagnostic validity of the Infant Gastroesophageal Reflux Questionnaire. Clin Pediatr (Phila). 1996;35:607-614.

20.

Orenstein SR , Cohn JF , Shalaby TM , Kartan R. Reliability and validity of an Infant Gastroesophageal Reflux Questionnaire. Clin Pediatr (Phila ). 1993;32: 472-484.

21.

Bishop J. , Furman M. , Thomson M. Omeprazole for gastroesophageal reflux disease in the first 2 years of life: a dose-finding study with dual-channel pH monitoring. J Pediatr Gastroenterol Nutr. 2007;45:50-55.

22.

Tolia V. , Ferry G. , Gunasekaran T. , Huang B. , Keith R. , Book L. Efficacy of lansoprazole in the treatment of gastroesophageal reflux disease in children. J Pediatr Gastroenterol Nutr. 2002;35(Suppl 4):S308-S318.

23.

Richter JE , Bochenek W. , Pantoprazole US ; GERD StudyGroup. Oral pantoprazole for erosive esophagitis: a placebo-controlled, randomized clinical trial. Am J Gastroenterol. 2000;95:3071-3080.

24.

Orenstein SR , Hassall E. , Furmaga-Jablonska W. , Atkinson S. , Raanan M. Multicenter, double-blind, randomized, placebo-controlled trial assessing the efficacy and safety of proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease. J Pediatr. 2009;154:514-520.

25.

Gilger MA , Tolia V. , Vandenplas Y. , Youssef NN , Traxler B. , Illueca M. Safety and tolerability of esomeprazole in children with gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr. 2008;46:524-533.

26.

Croom K. , Scott L. Lansoprazole: in the treatment of gastro-oesophageal reflux disease in children and adolescents. Drugs. 2005;65:2129-2135.

27.

Salvatore S. , Hauser B. , Vandemaele K. , Novario R. , Vandenplas Y.

Gastroesophageal reflux disease in infants: how much is predictable with questionnaires, pH-metry, endoscopy and histology?

J Pediatr Gastroenterol Nutr. 2005;40:210-215.

28.

Hassall E. , David I. , Ross S. , et al. Omeprazole for treatment of chronic erosive esophagitis in children: a multicenter study of efficacy, safety, tolerability and dose requirements . J Pediatr. 2000;137:800-807.